Skip to main content

Table 2 Expression levels of SRD5A1 in NSCLC and NAT samples as measured by qRT-PCR.

From: 5-alpha-reductase type I (SRD5A1) is up-regulated in non-small cell lung cancer but does not impact proliferation, cell cycle distribution or apoptosis

Primer target Analyzed biopsy Number
of samples
Average Ct Average
standard deviation
SRD5A1 #1 NAT 9 30.74 0.97
  tumor 23 29.25 1.37
SRD5A1 #2 NAT 9 31.30 1.16
  tumor 23 29.45 1.69
Cyclophilin NAT 9 21.28 0.52
  tumor 23 20.46 0.98
18S rRNA NAT 9 16.94 0.56
  tumor 23 17.01 0.67
  1. The analysis was performed on tumor samples from 23 patients, of which 9 provided NAT as well.
\